Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Inclusion Criteria: * Signed written Institutional Review Board/Ethical Committee approved informed consent form. * Male or female ≥18 years old. * Life expectancy ≥3 months. * ECOG Performance Status of 0-1. * Histologically confirmed hepatocellular carcinoma. * Not a candidate for curative treatments. * Child-Pugh A * Hematological, Biochemical and Organ Function: * AST (SGOT): ≤5.0 × ULN, * ALT (SGPT): ≤5.0 × ULN, * Total Bilirubin: ≤1.5mg/dL, * Platelets: ≥100,000/μL, * Absolute Neutrophil Count: ≥1,500/μL, * Serum creatinine: ≤2.0 × ULN, * PT-INR: ≤2.0 * Ability to provide a tumor tissue sample either by: * A formalin fixed paraffin embedded block sample within 12 months prior to informed consent for HCC diagnosis * Undergo a biopsy to confirm HCC diagnosis * Measurable disease. Exclusion Criteria: * Child-Pugh B or C * Patient who have taken Sorafenib previously. * Difficulty or inability to swallow pills. * Pregnant or lactating women or women of child-bearing potential and men of childbearing potential not willing to use effective means of contraception. * Patients known to be positive for Human immunodeficiency virus infection. * Active infectious diseases requiring treatment except for hepatitis B and C. * Other malignancies within the last 5 years. * History of transplantation (organ, bone marrow transplantation, Peripheral blood stem cell transplantation, etc.). * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. * Patients with known brain metastases or other central nervous system disease/disorders. * Uncontrolled hypertension defined as systolic blood pressure \>150 mmhg or diastolic blood pressure \>90 mmHg, despite optimal medical management. * Non-tumor related thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months. * Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 3, any other hemorrhage/bleeding event ≥ CTCAE Grade 4 within 4 weeks of first dose of study drug. * Serious non-healing wound, ulcer, or bone fracture. * Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1(6 weeks for nitrosoureas, mitomycin, and bevacizumab; 1 week for tumor biopsy). * Patients who received the following treatments within 2 weeks prior to Day 1: * Anticoagulant or thrombolytic agents for therapeutic purposes, * Systemic anti-viral therapy for hepatitis C and Interferon therapy for hepatitis B, * Blood transfusion including all blood products * Known history of hypersensitivity to similar agents. * Patients receiving any medications or substances that are inducers of CYP3A4 are ineligible: rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital and dexamethasone. * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.